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Abstract. 
 
The amyloid-
 
b 
 
peptide (A
 
b
 
) is produced at 
several sites within cultured human NT2N neurons with 
A
 
b
 
1-42 specifically generated in the endoplasmic retic-
ulum/intermediate compartment. Since A
 
b 
 
is found as 
insoluble deposits in senile plaques of the AD brain, 
and the A
 
b 
 
peptide can polymerize into insoluble 
fibrils in vitro, we examined the possibility that A
 
b
 
1-40, 
and particularly the more highly amyloidogenic A
 
b
 
1-
42, accumulate in an insoluble pool within NT2N neu-
rons. Remarkably, we found that formic acid extraction 
of the NT2N cells solubilized a pool of previously unde-
tectable A
 
b 
 
that accounted for over half of the total in-
tracellular A
 
b
 
. A
 
b
 
1-42 was more abundant than A
 
b
 
1-40 
in this pool, and most of the insoluble A
 
b
 
1-42 was gen-
erated in the endoplasmic reticulum/intermediate com-
partment pathway. High levels of insoluble A
 
b 
 
were 
also detected in several nonneuronal cell lines engi-
neered to overexpress the amyloid-
 
b 
 
precursor protein. 
This insoluble intracellular pool of A
 
b 
 
was exception-
ally stable, and accumulated in NT2N neurons in a 
time-dependent manner, increasing 12-fold over a 7-wk 
period in culture. These novel findings suggest that A
 
b 
 
amyloidogenesis may be initiated within living neurons 
rather than in the extracellular space. Thus, the data 
presented here require a reexamination of the prevail-
ing view about the pathogenesis of A
 
b 
 
deposition in the 
AD brain.
 
A
 
lzheimer’s
 
 disease (AD)
 
1
 
 is characterized by accu-
mulation of fibrillar amyloid-
 
b 
 
peptides (A
 
b
 
) in
senile plaques. That the accumulation of A
 
b 
 
is es-
sential for the pathogenesis of AD is supported by genetic
studies showing that mutations in the amyloid-
 
b 
 
precursor
protein (APP) (which gives rise to A
 
b 
 
through proteolytic
processing) are linked to a subset of familial AD (FAD)
cases with autosomal penetrance, and alter A
 
b 
 
production
(reviewed in Selkoe, 1997). For example, the double muta-
tion found in a Swedish FAD kindred leads to overpro-
duction of A
 
b
 
, while other mutations alter the relative lev-
els of the two major forms of A
 
b
 
, resulting in an increased
A
 
b
 
1-42/1-40 ratio (Citron et al., 1992; Scheuner et al.,
1996). Previous studies have shown that A
 
b
 
1-42 is more
insoluble than the more abundant A
 
b
 
1-40, and that it is
the most prevalent A
 
b 
 
species found in senile plaques
(Iwatsubo et al., 1994). Other FAD mutations that account
for the majority of early-onset FAD cases have been
linked to the 
 
Presenilin 1
 
 (
 
PS1
 
) and 
 
Presenilin 2
 
 (
 
PS2
 
)
genes (Levy-Lahad et al., 1995; Sherrington et al., 1995).
Mutations in these genes, like some of those in the APP
gene, also increase the A
 
b
 
1-42/1-40 ratio (Borchelt et al.,
1996; Duff et al., 1996; Scheuner et al., 1996).
Since genetic studies have established a role for A
 
b 
 
in
the pathogenesis of AD, it is essential to understand how
A
 
b 
 
is produced from APP. For example, it has been
shown that APP is cleaved by 
 
b
 
-secretase(s) to generate
the NH
 
2
 
 terminus of A
 
b
 
, and by 
 
g
 
-secretase(s) to generate
the COOH terminus of A
 
b 
 
(Haass et al., 1992; Shoji et al.,
1992). These cleavages may occur in a variety of subcellu-
lar locations, including the endoplasmic reticulum/inter-
mediate compartment (ER/IC; Chyung et al., 1997; Cook
et al., 1997; Hartmann et al., 1997; Xu et al., 1997), the
trans-Golgi network (TGN; Xu et al., 1997), and the endo-
somal/lysosomal system (Koo and Squazzo, 1994). Whereas
A
 
b 
 
produced by these pathways may be secreted (as has
been shown for TGN-generated A
 
b
 
) or may remain intra-
cellular (as has been shown for A
 
b 
 
generated by the ER/
IC pathway), the relative roles of intracellular and se-
creted A
 
b 
 
in the pathogenesis of AD remain to be deter-
mined.
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 Abbreviations used in this paper
 
: A
 
b
 
, amyloid-
 
b 
 
peptide; AD, Alz-
heimer’s disease; APP, amyloid-
 
b 
 
precursor protein; BHK, baby hamster
kidney; ER/IC, endoplasmic reticulum/intermediate compartment
 
; 
 
FAD,
Familial Alzheimer’s disease; SFV, Semliki Forest Virus; SFV-APPwt,
SFV expressing wild-type APP695; TGN, trans-Golgi network. 
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While numerous studies have documented that nonneu-
ronal cells engineered to express APP secrete both A
 
b
 
1-40
and A
 
b
 
1-42, intracellular A
 
b 
 
is not commonly seen in
these cells (Forman et al., 1997; Xu et al., 1997). However,
intracellular A
 
b 
 
can be detected readily in human NT2N
neurons after metabolic labeling, and its production pre-
cedes that of secreted A
 
b 
 
(Wertkin et al., 1993; Turner et
al., 1996). Analysis of intracellular A
 
b 
 
by ELISA indicates
that intracellular and secreted A
 
b 
 
are composed of differ-
ent ratios of A
 
b
 
1-42/1-40, with A
 
b
 
1-40 being more preva-
lent in secreted material (Turner et al., 1996). In addition
to being produced by mechanisms with different time
courses, and being composed of different proportions of
A
 
b
 
1-40 and A
 
b
 
1-42, intracellular and secreted A
 
b 
 
can be
produced by different pathways in NT2N neurons. Recent
studies have shown that A
 
b
 
1-42, but not A
 
b
 
1-40, is pro-
duced by an ER/IC pathway, and that this pathway does
not contribute to the secreted pool of A
 
b 
 
(Cook et al.,
1997). Finally, secretion of A
 
b 
 
by NT2N neurons increases
with time in culture (Turner et al., 1996). An age-depen-
dent increase in A
 
b 
 
secretion by neurons in vivo may play
a role in the deposition of A
 
b 
 
into senile plaques in the ex-
tracellular space of the brain during normal aging and in
AD, as well as in the cortex and hippocampus of trans-
genic mice that overexpress mutant forms of APP (Games
et al., 1995; Hsiao et al., 1996).
In addition to forming insoluble extracellular plaques,
A
 
b 
 
may also accumulate intracellularly in an aggregated
insoluble pool. For example, exogenous A
 
b
 
1-42 added to
culture medium can be taken up by cells, after which it can
be solubilized only by formic acid extraction (Knauer et al.,
1992; Yang et al., 1995). Thus, these findings raise the pos-
sibility that endogenously produced intracellular A
 
b 
 
may
aggregate within neurons as well. Because formic acid is
required to solubilize A
 
b 
 
from senile plaques, we sought
to detect the presence of insoluble A
 
b 
 
within NT2N neu-
rons and other cell lines by formic acid extraction, and
found that a significant fraction of the total intracellular
A
 
b
 
, particularly A
 
b
 
1-42, was retained as an insoluble pool
within these cells. Further, this insoluble pool of A
 
b 
 
in-
creased 12-fold in postmitotic NT2N neurons over a pe-
riod of 7 wk in culture. Since the prevailing view of amy-
loidogenesis in AD is that plaque formation is initiated in
the extracellular space by secreted A
 
b
 
, our findings chal-
lenge this assumption by implicating the intracellular com-
partment as a site where A
 
b 
 
may accumulate in an insolu-
ble form.
 
Materials and Methods
 
Cell Culture
 
NT2 cells derived from a human embryonal carcinoma cell line (Ntera2/
cl.D1) were grown and passaged as described previously (Pleasure et al.,
1992; Pleasure and Lee, 1993). Cells were differentiated by two weekly re-
tinoic acid treatments (10 
 
m
 
M) for 5 wk, and were replated (replate 2
cells) in the presence of mitotic inhibitors to yield nearly pure NT2N neu-
rons (Pleasure et al., 1992). To obtain
 
 
 
99% pure neurons (replate 3 cells),
replate 2 cells were removed enzymatically and mechanically, and were
replated in 10-cm dishes (Pleasure et al., 1992). Cultures of Replate 2 or
Replate 3 NT2N cells were used for experiments when they were 3–4 wk
old unless otherwise indicated. CHO Pro5 cells were grown and passaged
three times per week in Alpha-MEM (Life Technologies, Inc., Gaithers-
burg, MD) containing 10% FBS and penicillin/streptomycin. Baby ham-
ster kidney (BHK-21) cells were grown and passaged three times per
week in Glascow MEM (Life Technologies, Inc.) supplemented with 10%
tryptose phosphate, 5% FBS, and 0.02 M Hepes. CHO-695 cells were ob-
tained from Dr. S.S. Sisodia, and were grown and passaged as described
above for CHO Pro5 cells with the addition of 0.2 mg/ml of G418 to the
culture medium.
 
Preparation of Semliki Forest Virus and Infection of 
Cultured Cells
 
Semliki Forest Virus (SFV) expressing wild-type APP695 (SFV-APPwt)
or an APP mutant in which the third and fourth amino acids from the car-
boxyl terminus of APP have been changed to lysines (SFV-APP
 
D
 
KK)
were prepared and titered as previously described (Chyung et al., 1997;
Cook et al., 1997). CHO-Pro5, BHK-21, NT2, and NT2N cells were in-
fected in serum-free medium at a multiplicity of infection of 
 
z
 
10. After 1 h,
complete growth medium was replaced and infection was allowed to pro-
ceed for 12 h.
 
Metabolic Labeling, Immunoprecipitation, and
Gel Electrophoresis
 
Cultured NT2N cells were methionine-deprived by incubation in methio-
nine-free DMEM (Life Technologies, Inc.) for 30 min before adding
[S
 
35
 
]methionine (500 
 
m
 
Ci/ml in methione-free DMEM 
 
1
 
 5% dialyzed
FBS; DuPont-NEN, Boston, MA) for a 12-h labeling period. Cells were
washed twice in PBS and lysed in 600 
 
m
 
l RIPA buffer (0.5% sodium deox-
ycholate, 0.1% SDS, 1% NP40, 5 mM EDTA in TBS, pH 8.0) with a cock-
tail of protease inhibitors (1 
 
m
 
g/ml each of Pepstatin A, Leupeptin, TPCK,
TLCK, STI, and 0.5 mM PMSF). After brief sonication, cell lysates were
centrifuged at 40,000 
 
g
 
 for 20 min at 4
 
8
 
C, and the supernatant was sub-
jected to immunoprecipitation with 6E10 (a monoclonal antibody specific
for A
 
b
 
1-17; Kim et al., 1988) as previously described (Turner et al., 1996).
The remaining pellets were resuspended in 100 
 
m
 
l 70% formic acid and
sonicated until clear. For direct extraction into formic acid, cells were
scraped in 1 ml PBS, pelleted by centrifugation, and lysed in 100 
 
m
 
l of 70%
formic acid with sonication. Formic acid from both directly extracted and
sequentially extracted samples was removed by vacuum centrifugation for
40 min, and the resulting dry pellet was resuspended in 100 
 
m
 
l of 60% ace-
tonitrile. RIPA buffer (1.9 ml) was added to each of the samples before
they were subjected to immunoprecipitation with 6E10. Immunoprecipi-
tated A
 
b 
 
was resolved on a 10/16.5% step gradient Tris-Tricine gel, fixed
in 60% methanol, dried, and placed on PhosphorImager (Molecular Dy-
namics, Inc., Sunnyvale, CA) plates for 72 h.
 
Trypsin Treatment of CHO Cells
 
CHO Pro5 cells were infected with SFV-APPwt for 12 h, rinsed twice in
PBS, and incubated on ice for 20 min in either PBS alone, 10 
 
m
 
g/ml of
trypsin (Life Technologies, Inc.) in PBS, or 10 
 
m
 
g/ml trypsin plus 0.1%
Triton X-100 in an adaptation of a previously described technique (Turner
et al., 1996; Chyung et al., 1997). Trypsin was then inactivated by adding
100 
 
m
 
g/ml soybean trypsin inhibitor. The treated cells were then washed
with ice-cold PBS, scraped into PBS buffer, centrifuged at 2,000 
 
g
 
 for 2
min, resuspended in 100 
 
m
 
l formic acid, sonicated, and centrifuged at
40,000 
 
g
 
 for 20 min at 4
 
8
 
C. The supernatant was neutralized with 1.9 ml of
1 M Tris base and diluted 1:3 in H
 
2
 
O for quantification of A
 
b
 
1-40 and
A
 
b
 
1-42 by sandwich-ELISA.
 
Lysis of Cells and Sandwich ELISA
 
For serial extraction in RIPA and formic acid, cells were washed twice in
PBS and then lysed in 600 
 
m
 
l RIPA buffer and centrifuged for 20 min at
40,000 
 
g
 
 at 4
 
8
 
C. Supernatant was subjected directly to sandwich ELISA,
and the pellet was resuspended in 100 
 
m
 
l 70% formic acid with sonication
until clear. Formic acid samples were then neutralized by adding 1.9 ml
1 M Tris base and diluted 1:3 in H
 
2
 
O before quantifying Ab by sandwich-
ELISA.
For direct extraction into formic acid, cells were scraped in PBS after
washing twice with PBS. Cells were pelleted by centrifugation at 2,000 g
for 2 min, and were then lysed in 100 ml formic acid. Insoluble material
was pelleted by centrifugation at 40,000 g at 48C for 20 min, and the super-
natant was neutralized by adding 1.9 ml 1 M Tris base and diluted 1:3 in
H2O before quantification of Ab by sandwich-ELISA.
For extraction into PBS, cells were scraped in PBS after washing twiceSkovronsky et al. Accumulation of Insoluble Ab in Neurons 1033
with PBS. Cells were lysed by sonication, and insoluble material was pel-
leted by centrifugation at 40,000 g at 48C for 20 min, and Ab in the soluble
fraction was quantitated by sandwich-ELISA.
Sandwich-ELISA was performed as described previously using mAbs
specific for different species of Ab (Suzuki et al., 1994; Turner et al.,
1996). BAN-50 (a mAb specific for the first 10 amino acids of Ab) was
used as a capturing antibody, and horseradish peroxidase–conjugated BA-27
(a mAb specific for Ab1-40) and horseradish peroxidase–conjugated BC-05
(a mAb specific for Ab1-42) were used as secondary antibodies. To cali-
brate the sensitivity of the ELISA for detecting Ab after formic acid ex-
traction and neutralization, synthetic Ab1-40 and Ab1-42 peptides
(Bachem Bioscience Inc., King of Prussia, PA) used to generate the stan-
dard curves were treated with formic acid and neutralized in the same
manner as the cell lysates. Under these conditions, the sandwich ELISA
had a detection limit of ,1 femtomole of synthetic Ab per sample. The
BAN50, BA-27, and BC-05 mAbs were prepared and characterized as de-
scribed previously (Suzuki et al., 1994).
Cycloheximide Treatment
For experiments involving cycloheximide treatments, NT2N cells were in-
cubated in media containing 150 mg/ml cycloheximide for various time
points up to 24 h. Cells were harvested and extracted sequentially in
RIPA and formic acid as described above. Samples were then subjected to
sandwich ELISA analysis.
Western Blot Analysis of APP Levels
RIPA-extracted cell lysates (15 mg as determined by BCA assay) were re-
solved on a 7.5% Tris-glycine acrylamide gel and transferred to nitrocellu-
lose for immunoblotting with Karen (a goat anti–APP antibody) at a 1:1,000
dilution (Turner et al., 1996; Chyung et al., 1997). After application of a
rabbit anti–goat IgG linker, [125I]Protein A was applied, and radiolabeled
APP was quantitated by PhosphorImager analysis.
Results
Neurons Contain Insoluble Amyloid b Peptide
To evaluate the possibility that Ab exists in multiple in-
tracellular pools with different solubility characteristics,
NT2N neurons were sequentially extracted in aqueous
buffer (PBS), detergent buffer (RIPA), and then 70% for-
mic acid. The levels of Ab1-40 and Ab1-42 present in each
fraction were quantified by sandwich-ELISA. Previous
studies have shown that nonionic detergents liberate intra-
cellular Ab, but not Ab deposited in senile plaques or
fibrillar Ab formed in vitro (Selkoe et al., 1986; Burdick et al.,
1992; Harigaya et al., 1995; Turner et al., 1996). However,
more rigorous solubilization methods using 70% formic
acid liberate Ab from these insoluble aggregates. Sonica-
tion of cells in PBS in the absence of detergent failed to re-
lease any soluble Ab (data not shown). By contrast, signif-
icant levels of Ab1-40 and Ab1-42 were solubilized by
RIPA buffer. Nonetheless, RIPA buffer released only a
fraction of the total intracellular Ab since subsequent ex-
traction of the detergent-insoluble material with 70% for-
mic acid revealed a much larger pool of both Ab species
(Fig. 1 A). Since increased production of Ab1-42 relative
to Ab1-40 has been associated with AD (Borchelt et al.,
1996; Duff et al., 1996; Scheuner et al., 1996), we examined
the ratios of these Ab species in the detergent-soluble and
-insoluble pools in NT2N neurons. The ratio of Ab1-42/1-40
in the RIPA soluble pool was 1.0 6 0.1 (Fig. 1 B), consis-
tent with previous studies in a variety of experimental sys-
tems (Cook et al., 1997; Forman et al., 1997). However,
Ab1-42 was more abundant in the detergent-insoluble
pool, with an Ab1-42/1-40 ratio of 2.7 6 0.3 (Fig. 1 B).
This finding is consistent with the reduced solubility of
Ab1-42 relative to Ab1-40 in vitro, and the predominance
of Ab1-42 in insoluble deposits in the AD brain (Jarrett et
al., 1993a; Iwatsubo et al., 1994).
The identification of a large and previously undetected
pool of insoluble Ab in NT2N neurons prompted us to es-
tablish precise conditions for reproducible recovery of the
maximum amount of formic acid–extractable Ab. Sonica-
tion was found to be necessary for efficient Ab extraction,
and a volume of 100 ml formic acid was found to extract
Ab optimally from cell lysates containing z1 mg of total
protein. However, longer incubation times in formic acid
(up to 24 h) or high incubation temperatures (up to 378C)
did not increase Ab recovery (data not shown). To con-
firm that formic acid–extracted Ab was present in intracel-
lular compartments and not attached to the cells or culture
dish, cells were treated with trypsin in the presence or
absence of 0.1% Triton X-100. We found that formic acid–
solubilized intracellular Ab was resistant to trypsin diges-
tion in the absence of detergent, but sensitive to trypsin di-
gestion after solubilization by Triton X-100 (data not
shown). This finding indicates that the formic acid–soluble
pool of Ab is located intracellularly, and is accessible to
trypsin only when cell membranes are first permeabilized
by detergent. Finally, we found that cells extracted directly
into formic acid yielded amounts of Ab similar to the sum
of RIPA-soluble and RIPA-insoluble Ab (Fig. 1 A). From
these studies, we concluded that neurons contain at least
two major pools of intracellular Ab: a detergent soluble
pool, and a larger formic acid soluble pool that is enriched
in Ab1-42.
Insoluble Ab is Present in a Range of APP-Expressing 
Cell Types
To determine if insoluble intracellular Ab is present in cell
types other than neurons, NT2, CHO Pro5, and BHK-21
cells were sequentially extracted with RIPA followed by
formic acid, and Ab levels were measured by sandwich-
ELISA (Fig. 2). To evaluate the consequences of in-
creased APP production on the generation of soluble and
insoluble intracellular Ab, each cell type was also infected
with a recombinant SFV vector that led to the expression
of high levels of APP695. Additionally, Ab levels in stably
transfected CHO cells expressing APP695 (CHO-695)
were examined (Fig. 2 A). Steady-state APP levels present
in each cell type were determined by Western blotting in
order to correlate the levels of intracellular Ab with APP
(Fig. 2 B).
In contrast to NT2N neurons, retinoic acid naïve NT2
cells did not produce significant amounts of Ab, despite
expressing nearly equivalent levels of APP (Fig. 2, A and
B). This observation is consistent with previous experi-
ments that have demonstrated that NT2 cells do not effi-
ciently process APP by the b-secretase pathway, and thus
generate only low levels of Ab (Wertkin et al., 1993; For-
man et al., 1997). Furthermore, the engineered expression
of APP695 in NT2 cells at levels similar to those found in
NT2N neurons resulted in only a modest increase in intra-
cellular Ab levels (Fig. 2, A and B), indicating that the
lack of intracellular Ab in NT2 cells relative to NT2N neu-
rons was not due to differential expression of APP iso-The Journal of Cell Biology, Volume 141, 1998 1034
forms in the two cell types (APP751/770 in NT2 cells vs.
APP 695 in NT2N cells), but to differential processing of
APP. In addition, the fact that only low levels of Ab were
detected by sandwich-ELISA in this cell line further con-
firms that this assay is highly specific for Ab, and does not
significantly cross-react with other cellular proteins, in-
cluding full-length APP, other Ab-containing carboxy-ter-
minal fragments, or non-Ab APP–derived fragments.
CHO Pro5 and BHK-21 cells expressed barely detect-
able levels of APP, and they did not produce detectable
levels of soluble or insoluble Ab, further confirming the
specificity of the Ab ELISA. CHO-695 cells, however, did
produce intracellular Ab, 22 6 3% of which was insoluble
(Fig. 2 A). Likewise, infection of CHO Pro5 cells and
BHK-21 cells with SFV-APPwt led to a markedly in-
creased production of APP as well as intracellular Ab, of
which up to 74 6 5% was insoluble. This dramatic increase
in Ab production over a relatively short period of time
could favor Ab aggregation, resulting in a decrease in Ab
solubility. Indeed, CHO cells stably expressing APP con-
tained a much lower proportion of insoluble Ab than did
SFV-APP–infected CHO cells (Fig. 2 A).
These findings indicate that in addition to cell type–spe-
cific factors, the level of APP expression also governs dep-
osition of insoluble Ab. In cells that efficiently use the
b-secretase pathway to generate Ab, increased APP ex-
pression generally resulted in increased levels of both sol-
uble and insoluble Ab. However, while CHO-695 cells and
NT2N neurons both expressed similar levels of APP and
produced similar levels of soluble Ab, NT2N neurons ac-
cumulated significantly higher levels of insoluble Ab (Fig.
2; compare tracks labeled NT2N vs. CHO-695). This dif-
ference may be due to the higher metabolic rate of CHO-
695 cells, which may result in increased turnover of Ab,
thus hindering aggregation. Alternatively, Ab aggregation
in CHO-695 cells may be impeded by continual dilution
due to cell division. In postmitotic neurons, Ab may accu-
mulate intracellularly over time, and thus favor the forma-
tion of insoluble aggregates.
Taken together, these results indicate that while NT2N
neurons accumulate intracellular insoluble Ab as a conse-
quence of endogenous APP production, other cell types
also exhibit this property when they overexpress APP. It is
interesting to note that increased expression of APP in
NT2N neurons as a consequence of SFV-APPwt infection
did not result in increased levels of intracellular Ab1-42,
consistent with some of our previous work indicating that
g-secretase cleavage in the ER/IC pathway is rate-limiting
(Cook et al., 1997). By contrast, increased expression of
APP in NT2N neurons resulted in increased levels of in-
tracellular Ab1-40. That this increase was due solely to in-
creased levels of soluble Ab1-40 is consistent with this
form of Ab being produced late in the secretory pathway,
and being recovered from cells before secretion.
Ab Can be Immunoprecipitated from an Insoluble Pool
To further confirm that the material recovered by extrac-
tion with formic acid and measured by sandwich ELISA
was indeed Ab, SFV-APPwt–infected NT2N and CHO
cells were metabolically labeled with [35S]methionine for
12 h, and Ab was immunoprecipitated using 6E10. As
shown in Fig. 3, a band of z4 kD was immunoprecipitated
by an Ab-specific antibody in the RIPA-soluble cell lysate.
Additional Ab was immunoprecipitated from the RIPA-
insoluble (formic acid–extracted) cellular fraction, thus
confirming that a pool of Ab remained insoluble in RIPA
buffer, and could be extracted by formic acid (Fig. 3).
However, the yield of Ab after formic acid extraction was
lower than that predicted by Ab sandwich ELISA. To de-
termine if formic acid extraction compromised the recov-
ery of Ab by immunoprecipitation, [35S]methionine-labeled
SFV-APPwt–infected cells were extracted directly into
formic acid. Direct extraction of cells into formic acid would
be expected to yield amounts of Ab equal to the sum of
Ab extracted in the RIPA-soluble and -insoluble pools.
However, lower levels of Ab than expected were recov-
ered by this method (Fig. 3; compare lane 3 with lanes 1
and 2, and lane 6 with lanes 4 and 5). Thus, immunoprecip-
itation of formic acid–extracted cells was not quantitative,
and resulted in only partial recovery of Ab. This low
recovery of Ab may have been due to incomplete resolu-
bilization of Ab in acetonitrile after lyophilization, or re-
aggregation of Ab during immunoprecipitation. To evalu-
ate the contribution of each of these factors to the
incomplete recovery of Ab by immunoprecipitation, we
measured Ab levels in the formic acid–extracted cell ly-
sate before and after lyophilization and immunoprecipita-
tion by sandwich-ELISA. We found that z43% of formic
acid–extracted Ab could be resolubilized in acetonitrile
Figure 1. FA extraction of
NT2N neurons reveals a
large pool of insoluble intra-
cellular Ab. (A) 10-cm dishes
of NT2N cells (replate 2, 4
wk old) were either sequen-
tially extracted in RIPA fol-
lowed by FA, or lysed di-
rectly into FA. Ab1-40 and
Ab1-42 levels in the RIPA
and FA samples were quanti-
fied by sandwich ELISA.
Mean results and standard errors are shown (six separate experiments, each done with duplicate samples). (B) 1-42/1-40 ratios were cal-
culated for the RIPA soluble pool of Ab, the RIPA insoluble (FA soluble) pool of Ab, and the total intracellular pool of Ab for these
NT2N neurons, demonstrating that the insoluble intracellular pool of Ab consists mainly of Ab1-42, while the soluble pool contains sim-
ilar amounts of Ab1-40 and Ab1-42.Skovronsky et al. Accumulation of Insoluble Ab in Neurons 1035
after lyophilization, and z45% of this resolubilized Ab
could be captured by immunoprecipitation with the anti-
body 6E10 (data not shown). Nevertheless, despite the
shortcomings of the immunoprecipitation protocol as com-
pared with the Ab sandwich-ELISA, these data confirm
that the formic acid–extracted pool does indeed contain Ab.
Differential Production of Insoluble Ab1-40 and
Ab1-42 in Subcellular Compartments
While it has been shown that secreted Ab is mainly pro-
duced in the TGN, intracellular Ab 1-42, but not Ab1-40,
is produced in the ER/IC (Cook et al., 1997). To deter-
mine if Ab1-42 produced in the ER/IC enters the insolu-
ble pool, NT2N neurons and CHO Pro5 cells were infected
with SFV-APPwt or SFV-APPDKK (an APP mutant con-
taining the dilysine ER retrieval sequence). Infection of
both cell types with SFV-APPDKK gave similar results: al-
most a complete abrogation of Ab1-40 production, with
no diminution of Ab1-42 production relative to SFV-APPwt
infected cells (Fig. 4, A and B). Importantly, the levels of
insoluble Ab1-42 were the same in SFV-APPwt and SFV-
APPDKK–infected cells. These results demonstrate that
Ab1-42 produced in the ER/IC pathway represents the
bulk of the insoluble Ab1-42 inside cells. By contrast, in-
soluble Ab1-40 is produced by a post-ER/IC pathway. Fi-
nally, these results also prove that insoluble Ab can accu-
mulate in the absence of secretion, and they provide
additional evidence that the Ab solubilized by formic acid
is intracellular.
Time-dependent Accumulation of Insoluble Ab
Our previous studies have shown that secretion of Ab1-40
and Ab1-42 by the NT2N neurons increases with time in
culture without an increase in APP synthesis (Turner et al.,
1996). However, a time-dependent increase in intracellu-
lar Ab was not detected. Conversely, we found that reten-
tion of APP in the ER/IC resulted in continued production
of Ab1-42, but without either secretion or intracellular ac-
cumulation (Cook et al., 1997). Our observation here that
intracellular Ab (particularly the Ab1-42 species pro-
duced in the ER/IC) forms an insoluble pool provided a
Figure 2. FA extraction of a variety of cell lines reveals the pres-
ence of varying levels of insoluble intracellular Ab. (A) Unin-
fected and SFV-APPwt-infected NT2 cells, NT2N cells (replate 2,
4 wk old), CHO Pro5 cells, CHO-695 cells (uninfected only), and
BHK-21 cells were sequentially extracted in RIPA followed by
FA. Ab 1-40 and 1-42 levels in the RIPA and FA samples were
quantified by sandwich ELISA. Means and standard errors (four
separate experiments done in triplicate) of Ab levels are shown.
(B) Samples from RIPA cell lysates of each of these cell lines
(both uninfected and SFV-APPwt infected) were resolved on a
7.5% Tris-glycine acrylamide gel, and immunoblotted with Karen
antibody; bands were detected by PhosphorImager after using an
I125-labeled secondary antibody.
Figure 3. Ab can be recovered from RIPA-soluble and RIPA-
insoluble (FA-solubilized) fractions of cell lysate. SFV-APPwt–
infected NT2N cells and CHO Pro5 cells were metabolically
labeled for 12 h before being lysed in either FA or RIPA, fol-
lowed by extraction of insoluble material by FA. RIPA and FA
samples were subjected to immunoprecipitation with 6E10, and
were resolved on a 10/16.5% step gradient Tris-tricine gel. Molec-
ular weight standards and Ab bands are labeled.The Journal of Cell Biology, Volume 141, 1998 1036
possible explanation for both of these earlier findings. To
test the hypothesis that insoluble Ab can accumulate in-
tracellularly over time, NT2N neurons were analyzed at
various time points after replating by sequential extraction
in RIPA and formic acid, followed by sandwich-ELISA
for Ab quantitation. We found a dramatic increase (12-
fold over 7 wk in culture) in the levels of formic acid–
extractable intracellular Ab1-40 and Ab1-42 in NT2N
cells concomitant with increased time in culture (Fig. 5, A
and B). In addition to an increase in the absolute amount
of insoluble Ab with longer times in culture, an increase in
the fraction of insoluble Ab was also observed. For exam-
ple, at 4 wk, z58% of Ab was insoluble, while at 7 wk
z78% of Ab was insoluble (Fig. 5, A and B). This result
suggests that the equilibrium of soluble to insoluble Ab
may be shifted to favor insoluble Ab in NT2N cells that
were cultured longer (i.e., older neurons).
The Intracellular Accumulation of Ab Over Time
in Culture is Due to the Slow Turnover of Insoluble Ab
The time-dependent accumulation of insoluble intracellu-
lar Ab in neurons could be due to several factors, includ-
ing the slow turnover of insoluble Ab. To examine this
possibility, we treated NT2N cells with cycloheximide to
prevent protein synthesis, and measured endogenous lev-
els of Ab in the soluble and insoluble pools over time in
culture. This approach was needed (rather than a standard
pulse-chase analysis) because immunoprecipitation of Ab
after formic acid extraction was not quantitative (Fig. 3).
Fig. 6 shows that over the 24-h cycloheximide treatment,
soluble Ab1-40 and Ab1-42 decreased by z63% and z 77%,
respectively. Assuming a constant rate of degradation, we
calculated half-lives of z18 h and z12 h for the decay of
intracellular soluble Ab1-40 and Ab1-42, respectively. By
contrast, insoluble Ab1-40 and Ab1-42 levels did not de-
crease significantly over 24 h. The slow turnover of the in-
soluble pool of Ab precluded an accurate estimate of the
half-life of this pool. In addition, this analysis is compli-
cated by two factors. First, although no new APP will be
synthesized in the presence of cycloheximide, existing
pools of APP continue to be processed to generate Ab.
However, the half-life of APP in NT2N neurons is z3 h.
Thus, de novo production of Ab from existing pools of
APP is unlikely to contribute significantly to intracellular
Ab pools, especially at later time points. Second, soluble
Ab1-40 and Ab1-42 may enter the insoluble pool over
time, again making accurate estimates of turnover rates
difficult. Nevertheless, our results show that intracellular
insoluble Ab is very long-lived, and that this long life is
Figure 4. Insoluble Ab1-42
can be produced by APPDKK
expressing NT2N and CHO
cells. (A) N2TN cells and (B)
CHO Pro5 cells were in-
fected with SFV-APPwt or
SFV-APPDKK for 12 h be-
fore sequential extraction in
RIPA, followed by FA. Ab
in each sample was quanti-
fied by sandwich-ELISA.
Means and standard errors
(two separate experiments
each done in triplicate) are
shown.
Figure 5. Insoluble intracellu-
lar Ab accumulates over time
within NT2N cells. 10-cm
dishes of Replate 2 NT2N
cells were harvested each
week 3–7 wk after replating.
Cells were lysed in RIPA
buffer, and insoluble mate-
rial was resuspended in FA.
Ab1-40 (A) and 1-42 (B) in
the soluble and insoluble in-
tracellular pools were quanti-
fied by sandwich-ELISA.
Data were normalized for to-
tal protein present (in mg).
The experiment was re-
peated three times, and
means and standard errors
(three to five samples per
time point) are shown for a
representative experiment.Skovronsky et al. Accumulation of Insoluble Ab in Neurons 1037
likely to play an important role in the time-dependent ac-
cumulation of insoluble Ab we observed in NT2N cells
over weeks in culture.
Discussion
The presence of insoluble aggregates of Ab in senile
plaques is a well-characterized feature of AD (Selkoe,
1997). Ab is composed of two major species that terminate
at residues 40 and 42 of the intact Ab sequence. Both spe-
cies can be recovered from the CSF of normal and AD in-
dividuals, with Ab1-40 being approximately 10-fold more
abundant than Ab1-42 (Citron et al., 1992). However,
Ab1-42 is the major Ab species present in senile plaques,
with Ab1-40 being only a minor constituent (Iwatsubo et
al., 1994). That alterations in APP processing can lead to
development of AD has been shown by several FAD-asso-
ciated APP mutations that, when expressed in vitro or in
transgenic animals, lead to either an overall increase in Ab
production or an increase in the amount of Ab1-42 rela-
tive to Ab1-40 (Borchelt et al., 1996; Duff et al., 1996).
The differential production of Ab1-40 and Ab1-42 as a
consequence of AD-associated APP mutations as well as
the preferential deposition of Ab1-42 in senile plaques
raises important questions as to the intracellular sites of
Ab1-42 generation, the origin of Ab that is recovered
from senile plaques, and the factors that control its deposi-
tion.
Both Ab1-40 and Ab1-42 are constitutively produced
and secreted from cells in vitro and in vivo as judged by
their recovery from conditioned medium and CSF (Shoji
et al., 1992; Tamaoka et al., 1996). Since FAD-associated
APP mutations lead to increased secretion of Ab, and se-
nile plaques are extracellular lesions, it is possible that se-
creted Ab is ultimately deposited in senile plaques, even
though the factors controlling its deposition are obscure.
However, we have recently discovered that retention of
APP in the ER/IC induced by a variety of methods leads
to continued production of intracellular Ab1-42, but not
Ab1-40 (Cook et al., 1997). While Ab1-42 is constitutively
produced by this novel pathway in NT2N neurons, other
cell types can also process APP to generate Ab in the ER/
IC after overexpression of APP (Wild-Bode et al., 1997).
Ab1-42 has also been shown to be localized to the ER/IC
by immunoelectron microscopy and by cell fractionation
(Hartmann et al., 1997; Wild-Bode et al., 1997). Interest-
ingly, this compartment also is the site where PS1 and PS2
are localized (Cook et al., 1996; Kovacs et al., 1996). Since
mutations in PS1 and PS2 account for the majority of
early-onset FAD cases, and FAD-associated PS1 and PS2
mutations have been shown to result in an increased ratio
of Ab1-42/1-40 (Borchelt et al., 1996; Duff et al., 1996;
Scheuner et al., 1996), colocalization of the presenilins
with a major site of constitutive Ab1-42 production raises
the possibility that alterations in Ab production by the
ER/IC pathway may play an important role in AD patho-
genesis.
While retention of APP in the ER/IC resulted in contin-
ued and selective production of Ab1-42, we were unable
to document either secretion of this material or its intra-
cellular accumulation (Cook et al., 1997). Taken at face
value, this result indicates that the production and turn-
over of Ab1-42 by the ER/IC pathway are in equilibrium.
However, given the propensity of Ab1-42 to aggregate in
vivo and in vitro, we asked whether Ab1-42 also aggre-
gated intracellularly. Since formic acid has been shown to
effectively solubilize aggregated Ab present in senile
plaques, we solubilized cell lysates in formic acid. Using
this approach, we found that a considerable fraction of to-
tal intracellular Ab1-42, and to a lesser extent Ab1-40,
could be solubilized by formic acid, but not by a variety of
detergents. Currently, we do not know whether or not the
formic acid–extractable Ab self-aggregates or coaggre-
gates with other proteins. Our observation that none of
the cell-associated Ab (including that targeted for secre-
tion) can be extracted with aqueous buffer suggests that it
may be bound to other cellular proteins. On the other
hand, in vitro studies of Ab aggregation suggest that Ab is
prone to self-aggregation. Future ultrastructural studies on
the accumulated intracelullar Ab will help to resolve this
issue. Intracellular insoluble Ab was recovered in a num-
ber of different APP-expressing cell lines. Overexpression of
APP generally resulted in increased production of insoluble
Ab. However, insoluble Ab was produced most efficiently
Figure 6. The insoluble pool
of intracellular Ab is stable
over 24 h, while the soluble
pool of cellular Ab turns over
more rapidly. 10-cm dishes of
Replate 2 NT2N cells were
treated with 150 mg/ml cyclo-
hexamide for the times indi-
cated before being sequen-
tially extracted in RIPA and
FA. Ab1-40 and 1-42 in the
soluble (A) and insoluble in-
tracellular pools (B) were
quantified by sandwich-
ELISA. The experiment was
repeated three times, and
means and standard errors
(three samples per time
point) are shown for a repre-
sentative experiment.The Journal of Cell Biology, Volume 141, 1998 1038
in NT2N neurons. Thus, while aggregation of intracellular
Ab is not cell type–specific, the subcellular environment in
neurons appears to favor this process.
Identification of a novel form of intracellular Ab that
has previously escaped detection could explain our failure
to detect secretion or intracellular accumulation of Ab1-42
produced by the ER/IC pathway (Cook et al., 1997). To
test this possibility, we expressed APP bearing an ER/IC
retrieval signal in the cytoplasmic domain in NT2N neu-
rons and in CHO cells. Production of intracellular soluble
and insoluble Ab1-40 was almost completely inhibited af-
ter expression of this construct, while levels of soluble and
insoluble intracellular Ab1-42 were unchanged by ER re-
tention. Thus, almost all of the formic acid–soluble Ab1-42
can be derived from the ER/IC pathway. By extension, in-
soluble Ab1-40 must be produced by a post-ER/IC com-
partment. Production of insoluble Ab1-40 and Ab1-42 in
different subcellular compartments may help explain the
predominance of Ab1-42 in the intracellular pool. Ab1-40
is produced late in the biosynthetic pathway, and may
spend relatively little time in the cell before secretion,
thereby minimizing the opportunity for aggregation. By
contrast, the bulk of the intracellular Ab1-42 is produced
by the ER/IC pathway. This fact represents an environ-
ment distinct from that in which Ab1-40 is produced, and
one that does not result in Ab1-42 secretion. The long-
lived nature of Ab1-42, its continued production at an in-
tracellular site from which it cannot be secreted, and the
fact that it is intrinsically less soluble than Ab1-40 all may
contribute to its propensity to enter a stable, intracellular
pool of insoluble material. It will be important to define
further the factors that govern Ab deposition in this insol-
uble pool, and to more carefully study its physical state.
During the course of our experiments, we found that re-
covery of insoluble Ab from NT2N neurons was some-
what variable. However, we found that this result was due
to a time-dependent accumulation of Ab. Specifically, we
found that Ab levels increased by 12-fold as the NT2N
neurons aged over 7 wk in culture. While insoluble Ab1-40
and Ab1-42 accumulated at similar rates, more detailed
kinetic studies are needed to determine if production of
insoluble Ab1-40 and Ab1-42 is contemporaneous, or if
generation of insoluble Ab1-42 seeds subsequent poly-
merization of Ab1-40, as has been reported in vitro. In any
event, time-dependent accumulation of insoluble Ab
could be due to increased production, decreased turnover,
or stable accumulation of Ab at a relatively constant rate.
We found that intracellular insoluble Ab was exception-
ally stable. Thus, even slow addition of Ab to the insoluble
pool over weeks in culture could result in steady accumu-
lation of Ab seen in the insoluble pool over time. This ob-
servation may have implications for AD pathogenesis,
where it is thought that accumulation of Ab occurs slowly
over decades. Since AD is an age-dependent disease, the
data presented here suggest that gradual accumulation of
intracellular Ab may be a factor in the slow onset and pro-
gression of AD. It will be important to determine if accu-
mulation of intracellular insoluble Ab is simply the result
of the stability of this form of Ab, or if other time-depen-
dent factors (such as altered APP processing or neurotoxic
insults) contribute to this process.
Although intracellular b-amyloid fibrils have been ob-
served in the AD brain (Kim et al., 1988) as well as in a
transgenic mouse model of AD (Masliah et al., 1996), it is
unclear whether Ab fibrils can form within neurons from
endogenously produced Ab. The experiments presented
here demonstrate that significant levels of Ab are insolu-
ble within neurons. The observation that Ab can accumu-
late with time in a relatively stable insoluble pool may ex-
plain how Ab deposition in senile plaques can begin
despite relatively low levels of secreted and CSF-soluble
Ab1-42. Concentrated intracellular Ab1-42 could rapidly
nucleate fibril formation, and intracellularly produced
Ab1-42 and Ab1-40 could add to these fibrils over time,
thus serving as a nidus for a developing senile plaque.
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